The Dow Jones Industrial Average (DJIA), often simply referred to as "the Dow," stands as one of the most enduring and widely recognized stock market indices globally. It serves as a crucial barometer for the overall health of the U.S. stock market and, by extension, the broader economy. For
Investing in the S&P 500 offers a straightforward and effective way for individuals to gain diversified exposure to the U.S. stock market. As a benchmark tracking approximately 500 of the largest publicly traded companies in the United States, the S&P 500 is not an investment itself but
DAX is in higher degree consolidation within an uptrend, as we see it forming a bullish running triangle pattern that can send the price higher by Elliott wave theory.
NVIDIA Corporation (NASDAQ: NVDA) is a leading designer of graphics processing units (GPUs) for the gaming, professional visualization, data center, and automotive markets. As a bellwether for the semiconductor industry and a key player in the burgeoning artificial intelligence (AI) sector, NVIDIA's earnings reports are closely watched by investors and
Scholar Rock reports Q2 2025 loss of $0.98 per share but gains investor optimism ahead of FDA decision for apitegromab in SMA. Cash runway extends to 2027.
The U.S. and Japan announced a big trade deal that lowers tariffs to just 15% on imports, and the team discusses earnings from General Motors, Intuitive Surgical, and Enphase Energy.
Unfavorable weather in Q2 drove Six Flags' sales and attendance below expectations, sent shares down over 14%, and prompted a cut to its 2025 EBITDA outlook to $860–$910 million.
Jazz Pharmaceuticals (JAZZ) is a value stock with strong fundamentals, trading below industry averages in P/E and EV/EBITDA, while maintaining high profitability and steady growth potential.
Hims & Hers falls into a buying opportunity followng the Q2 release and guidance update but investors shouldn't rush to get in, wait for this market to bottom.
The company has reportedly entered a licensing agreement with Pairwise, an agricultural gene editing firm to speed up the development of hardier cocoa crops.
Discover the critical warning signs flashing in the S&P 500, from collapsing market breadth to volume spikes, and what they could mean for the next big sell-off.
Newspaper and digital media company The New York Times (NYSE:NYT) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 9.7% year on year to $685.9 million. Its non-GAAP profit of $0.58 per share was 12.7% above analysts’ consensus estimates.
Jones Lang LaSalle (JLL) Q2 2025 earnings beat EPS estimates at $3.30, but revenue slightly missed at $6.25B. Shares were flat as growth in key segments continued.
OPPFI Inc reports mixed Q2 2025 results with revenue slightly below estimates but EPS beating expectations by 50%. Adjusted net income hits a record high, driving a 12.8% pre-market stock surge.
Lantheus Holdings (LNTH) Q2 2025 earnings miss estimates, revenue down 4.1%. Shares drop 20.8% as weak guidance raises concerns. FDA accepts NDA for PYLARIFY upgrade.
Solo Brands Inc. (SBDS) Q2 2025 earnings missed revenue and EPS estimates, sparking a stock decline. Management cites restructuring for profitability, but weak sales growth raises investor concerns.
Game engine maker Unity (NYSE:U) reported Q2 CY2025 results exceeding the market’s revenue expectations, but sales fell by 1.9% year on year to $440.9 million. On the other hand, next quarter’s revenue guidance of $445 million was less impressive, coming in 0.6% below analysts’ estimates. Its non-GAAP profit of $0.18 per share was 22% above analysts’ consensus estimates.
Bioventus Inc. (BVS) reports mixed Q2 2025 results with slight revenue miss but EPS near estimates. Organic growth up 6.2%, yet stock dips 2% pre-market.
Vishay Intertechnology (VSH) missed Q2 2025 earnings and revenue estimates, posting a loss per share. Shares show mixed reaction amid broader declines. Analysts watch for Q3 recovery.
The New York Times Q2 2025 earnings beat estimates with $685.87M revenue and $0.58 EPS, driving a 5.37% pre-market stock surge. Subscriber growth and bundling strategies fuel optimism.
Banking and retail technology provider Diebold Nixdorf (NYSE:DBD) announced better-than-expected revenue in Q2 CY2025, but sales fell by 2.6% year on year to $915.2 million. Its GAAP profit of $0.33 per share was 17.5% below analysts’ consensus estimates.
